AJP - Endocrinology and Metabolism, Vol 269, Issue 6 E1095-E1100, Copyright © 1995 by American Physiological Society

ARTICLES

Effect of AVP and oxytocin on insulin release: involvement of V1b receptors

B. Lee, C. Yang, T. H. Chen, N. al-Azawi and W. H. Hsu
Department of Veterinary Physiology and Pharmacology, Iowa State University, Ames 50011, USA.

We used a number of receptor antagonists to determine which receptors mediate the effect of arginine vasopressin (AVP) and oxytocin (OT) on insulin release. We found that OT (10(-7) M) and AVP (10(-8) M) increased insulin release from the perfused rat pancreas with similar magnitude. The antagonist with potent V1b receptor-blocking activity, dP[Tyr(Me)2]AVP (10(-7) M), abolished the effect of OT and AVP, whereas the highly selective OT receptor antagonist L-366,948 (10(-6) M) did not change the effect of OT, nor did a V1a receptor antagonist, d(CH2)5[Tyr(Me)2]AVP (10(-7) M), change the effect of AVP. The insulin-releasing potency of OT was estimated as 9-fold less than that of AVP in RINm5F cells. Selected AVP and OT antagonists were used to study their antagonism on AVP- and OT-induced insulin release from RINm5F cells, and the order of potencies of antagonists was estimated as dP[Tyr(Me)2]AVP > d(CH2)5[D-Phe2,Ile4]AVP > SR-49059 > d(CH2)5[Tyr(Me)2]AVP > desGly9d(CH2)5[Tyr(Et)2]VAVP (WK-3-6) approximately L-366,948. These results were consistent with the V1b receptor antagonistic activities of the antagonists. d[D-3-Pal]VP, a V1b receptor agonist, increased insulin release dose dependently (10(-9) to 10(-6) M), and this effect was antagonized by dP[Tyr(Me)2]AVP but not by WK-3-6 (10(-6) M). These results suggested that the stimulatory effect of both OT and AVP on insulin release from beta-cells may be mediated by V1b, but not by V1a or OT receptors.

This article has been cited by other articles:

				A.-M. O'Carroll, G. M Howell, E. M Roberts, and S. J Lolait Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic {beta}-cells J. Endocrinol., May 1, 2008; 197(2): 231 - 239. [Abstract] [Full Text] [PDF]

				Y. Fujiwara, M. Hiroyama, A. Sanbe, T. Aoyagi, J.-i. Birumachi, J. Yamauchi, G. Tsujimoto, and A. Tanoue Insulin hypersensitivity in mice lacking the V1b vasopressin receptor J. Physiol., October 1, 2007; 584(1): 235 - 244. [Abstract] [Full Text] [PDF]

				N. Wettschureck and S. Offermanns Mammalian G Proteins and Their Cell Type Specific Functions Physiol Rev, October 1, 2005; 85(4): 1159 - 1204. [Abstract] [Full Text] [PDF]

				V. Folny, D. Raufaste, L. Lukovic, B. Pouzet, P. Rochard, M. Pascal, and C. Serradeil-Le Gal Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E566 - E576. [Abstract] [Full Text] [PDF]

				C. S.-L. Gal, J. Wagnon, J. Simiand, G. Griebel, C. Lacour, G. Guillon, C. Barberis, G. Brossard, P. Soubrie, D. Nisato, et al. Characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1122 - 1130. [Abstract] [Full Text] [PDF]

				S. Yibchok-Anun, H. Cheng, P. A. Heine, and W. H. Hsu Characterization of receptors mediating AVP- and OT-induced glucagon release from the rat pancreas Am J Physiol Endocrinol Metab, July 1, 1999; 277(1): E56 - E62. [Abstract] [Full Text] [PDF]